Hundreds of residents queue to get a booster shot vaccine for the COVID 19 coronaviruses in Bekasi on February 5, 2022. REZAS AFP JAKARTA BEIJING Indonesia said it granted emergency use approval for an mRNA COVID 19 vaccine developed by a Chinese company.
Indonesia's food and drugs agency has approved the use of Walvax Biotechnology's mRNA vaccine, which has been in development for more than two years, and targets the original strain of the coronaviruses.
Walvax has yet to publish its efficacy readings for its vaccine, which is now known as AWcorna, from its large late-stage trial, which would show how well it can reduce the risk of COVID cases and deaths from the disease.
It was not immediately clear how widely the newly approved shot will be used in Indonesia, where more than 63 percent of its population is fully vaccinated.
ALSO READ: Trials for new China-developed mRNA vaccines were greenlighted.
Indonesia uses mRNA COVID vaccines made by Pfizer- BioNTech and Moderna, but the AWcorna shot has a longer shelf life, remaining stable at 2 -- 8 degrees Celsius for at least six months, according to its researchers.
Walvax and a co-developer of the vaccine, Suzhou Abogen Biosciences, are working on their own mRNA candidates that target coronaviruses variants.